NIBR-17

CAS No. 944396-88-7

NIBR-17( —— )

Catalog No. M27568 CAS No. 944396-88-7

NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 263 In Stock
5MG 223 In Stock
10MG 332 In Stock
25MG 532 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NIBR-17
  • Note
    Research use only, not for human use.
  • Brief Description
    NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
  • Description
    NIBR-17 is a pan class I PI3K inhibitor. NIBR-17 inhibits PI3KKα, PI3KKβ, PI3KKγ, and PI3KKδ with IC50 of 1 nM, 9.2 nM, 9 nM, and 20 nM respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    DEPTOR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    944396-88-7
  • Formula Weight
    380.4
  • Molecular Formula
    C18H20N8O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COc(cc1)ncc1Nc1cc(-c2cnc(N)nc2)nc(N2CCOCC2)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hou Y, et al. Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment. J Med Chem. 2021 Oct 28;64(20):14942-14954.
molnova catalog
related products
  • SRX3207

    SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.

  • RLY-2608

    RLY-2608 is a selective mutant PI3Kα inhibitor that inhibits tumor growth in a PIK3CA mutant xenograft model.

  • A66

    A66 (p110α inhibitor A66) is a potent, highly specific p110α inhibitor.